Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
ORTHO-NOVUM 7/7/7-21 is an oral contraceptive tablet containing a fixed combination of norethindrone and ethinyl estradiol in a 21-day active dosing regimen. It prevents ovulation through hormonal suppression and is indicated for contraception in women of reproductive age. This is a legacy oral contraceptive product with a well-established safety and efficacy profile.
This legacy oral contraceptive faces competitive pressure from newer formulations and long-acting reversible contraceptives; expect reduced team investment and focus on retention over growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO-NOVUM 7/7/7-21 represents a mature product management opportunity within a commodity market, ideal for professionals seeking stability and deep expertise in regulatory maintenance and lifecycle optimization. Career growth is limited; this role emphasizes operational excellence, cost management, and risk mitigation rather than market expansion or innovation leadership.
Worked on ORTHO-NOVUM 7/7/7-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.